Fate Therapeutics, Inc.

NasdaqGM:FATE Stock Report

Market Cap: US$149.2m

Fate Therapeutics Valuation

Is FATE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FATE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FATE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FATE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FATE?

Key metric: As FATE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FATE. This is calculated by dividing FATE's market cap by their current revenue.
What is FATE's PS Ratio?
PS Ratio11.6x
SalesUS$13.45m
Market CapUS$149.20m

Price to Sales Ratio vs Peers

How does FATE's PS Ratio compare to its peers?

The above table shows the PS ratio for FATE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
MCRB Seres Therapeutics
1.2x-35.8%US$137.5m
CHRS Coherus BioSciences
0.5x6.2%US$140.6m
ENTA Enanta Pharmaceuticals
1.6x0.6%US$105.5m
ELUT Elutia
4.3x45.7%US$103.3m
FATE Fate Therapeutics
11.6x36.3%US$149.2m

Price-To-Sales vs Peers: FATE is expensive based on its Price-To-Sales Ratio (11.6x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does FATE's PS Ratio compare vs other companies in the US Biotechs Industry?

138 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.2x1.2%US$21.04b
MRNA Moderna
3.1x10.2%US$15.67b
INCY Incyte
3.5x5.4%US$14.20b
EXAS Exact Sciences
3.9x9.3%US$10.16b
FATE 11.6xIndustry Avg. 10.1xNo. of Companies138PS01632486480+
138 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: FATE is expensive based on its Price-To-Sales Ratio (11.6x) compared to the US Biotechs industry average (10.1x).

Price to Sales Ratio vs Fair Ratio

What is FATE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FATE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.6x
Fair PS Ratio0.004x

Price-To-Sales vs Fair Ratio: FATE is expensive based on its Price-To-Sales Ratio (11.6x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FATE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.37
US$6.31
+360.4%
35.9%US$10.00US$3.00n/a13
Jan ’26US$1.65
US$6.31
+282.3%
35.9%US$10.00US$3.00n/a13
Dec ’25US$3.17
US$6.31
+99.0%
35.9%US$10.00US$3.00n/a13
Nov ’25US$2.43
US$6.46
+165.8%
39.4%US$12.00US$3.50n/a12
Oct ’25US$3.35
US$6.46
+92.8%
39.4%US$12.00US$3.50n/a12
Sep ’25US$3.67
US$6.46
+76.0%
39.4%US$12.00US$3.50n/a12
Aug ’25US$4.88
US$6.79
+39.1%
34.4%US$12.00US$4.00n/a14
Jul ’25US$3.26
US$6.79
+108.2%
34.4%US$12.00US$4.00n/a14
Jun ’25US$3.68
US$6.64
+80.5%
36.7%US$12.00US$4.00n/a14
May ’25US$4.09
US$7.80
+90.7%
25.7%US$12.00US$5.00n/a15
Apr ’25US$7.08
US$7.80
+10.2%
25.7%US$12.00US$5.00n/a15
Mar ’25US$7.74
US$7.50
-3.1%
33.7%US$12.00US$2.00n/a14
Feb ’25US$6.76
US$6.23
-7.8%
50.5%US$13.00US$2.00n/a15
Jan ’25US$3.74
US$6.23
+66.7%
50.5%US$13.00US$2.00US$1.6515
Dec ’24US$2.65
US$6.23
+135.2%
50.5%US$13.00US$2.00US$3.1715
Nov ’24US$1.93
US$7.28
+276.9%
46.0%US$16.00US$4.00US$2.4316
Oct ’24US$2.12
US$7.28
+243.2%
46.0%US$16.00US$4.00US$3.3516
Sep ’24US$2.81
US$7.02
+149.9%
47.4%US$16.00US$4.00US$3.6717
Aug ’24US$3.97
US$8.11
+104.2%
40.0%US$16.00US$4.00US$4.8819
Jul ’24US$4.76
US$8.16
+71.4%
39.4%US$16.00US$4.00US$3.2619
Jun ’24US$5.07
US$8.16
+60.9%
39.4%US$16.00US$4.00US$3.6819
May ’24US$6.36
US$8.49
+33.5%
39.6%US$16.00US$4.00US$4.0919
Apr ’24US$5.70
US$8.32
+45.9%
40.5%US$16.00US$4.00US$7.0820
Mar ’24US$6.09
US$8.22
+34.9%
40.3%US$16.00US$4.00US$7.7420
Feb ’24US$6.37
US$8.47
+32.9%
40.1%US$16.00US$4.00US$6.7620
Jan ’24US$10.09
US$59.15
+486.2%
50.2%US$115.00US$10.00US$3.7420
Analyst Price Target
Consensus Narrative from 13 Analysts
US$6.31
Fair Value
78.3% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 01:01
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fate Therapeutics, Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research